Relugolix kombinovaná terapie a symptomy děložní myomatózy - vybrané kazuistiky indikačního spektra a výsledků léčby

HUDEČEK, Robert, J. KLAT, K. POHL, A. PROKOPENKO, L. MIKULASEK, Soňa ŠIMOVÁ, P. KRCAL, A. SEVCIK a P. TOMES. Relugolix kombinovaná terapie a symptomy děložní myomatózy - vybrané kazuistiky indikačního spektra a výsledků léčby. CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY. PRAGUE: NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2023, roč. 88, č. 5, s. 359-370. ISSN 1210-7832. Dostupné z: https://dx.doi.org/10.48095/cccg2023359.

Základní údaje

• Originální název: Relugolix kombinovaná terapie a symptomy děložní myomatózy - vybrané kazuistiky indikačního spektra a výsledků léčby
• Název anglicky: Relugolix combination therapy and symptoms of uterine myomatosis – selected case reports of indication spectrum and treatment outcomes
• Autoři: HUDEČEK, Robert (203 Česká republika, domácí), J. KLAT (203 Česká republika), K. POHL (203 Česká republika), A. PROKOPENKO (203 Česká republika), L. MIKULASEK (203 Česká republika), Soňa ŠIMOVÁ (703 Slovensko, domácí), P. KRCAL (203 Česká republika), A. SEVCIK (203 Česká republika) a P. TOMES (203 Česká republika).
• Vydání: CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY, PRAGUE, NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2023, 1210-7832.

Další údaje

• Originální jazyk: čeština
• Typ výsledku: Článek v odborném periodiku
• Obor: 30214 Obstetrics and gynaecology
• Stát vydavatele: Česká republika
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 0.400 v roce 2022
• Kód RIV: RIV/00216224:14110/23:00133866
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.48095/cccg2023359
• UT WoS: 001173222000001
• Klíčová slova česky: relugolix kombinovaná terapie; symptomy děložních myomů
• Klíčová slova anglicky: relugolix combination therapy; uterine fibroid symptoms
• Štítky: 14110240, rivok
• Příznaky: Recenzováno

Anotace

Objective: An illustrative review of the indications for relugolix combination therapy (RCT) in the management of symptoms associated with uterine myomatosis. Methods: A set of annotated case reports from outpatient and clinical practice. Results: The file includes a non-invasive methodology for defining excessive menstrual bleeding using the pictorial bleeding assessment chart (PBAC). It also presents the use of RCT as a fertility-sparing procedure prior to elective myomectomy and the management of isthmic fi broids as an uterine factor of infertility. Cases of RCT of adenomyosis in primary sterility and in extragenital forms of endometriosis are commented. Emergent events associated with complications of myomatosis in pregnancy are represented by a case report of necrotizing diffuse myomatosis in puerperium. The differential-diagnostic confusion of adnexal pathology and myomatosis, RCT as a final solution to failed pharmacotherapy, and the alternative of hysterectomy in premenopause illustrate the diverse spectrum of indications for pharmacological treatment, including the possibility of dual therapy with RCT and aGnRH. Conclusion: Relugolix combination therapy as an effective and safe causal treatment expands the therapeutic spectrum and options for reproductive medicine specialists and registering gynaecologists. The availability of conservative treatment in combination with surgical treatment leads to optimalization and greater effectiveness of therapeutic procedures and increased quality of life for women with myomatosis.

Anotace anglicky

Objective: An illustrative review of the indications for relugolix combination therapy (RCT) in the management of symptoms associated with uterine myomatosis. Methods: A set of annotated case reports from outpatient and clinical practice. Results: The file includes a non-invasive methodology for defining excessive menstrual bleeding using the pictorial bleeding assessment chart (PBAC). It also presents the use of RCT as a fertility-sparing procedure prior to elective myomectomy and the management of isthmic fibroids as an uterine factor of infertility. Cases of RCT of adenomyosis in primary sterility and in extragenital forms of endometriosis are commented. Emergent events associated with complications of myomatosis in pregnancy are represented by a case report of necrotizing diff use myomatosis in puerperium. The differential-diagnostic confusion of adnexal pathology and myomatosis, RCT as a final solution to failed pharmacotherapy, and the alternative of hysterectomy in premenopause illustrate the diverse spectrum of indications for pharmacological treatment, including the possibility of dual therapy with RCT and aGnRH. Conclusion: Relugolix combination therapy as an effective and safe causal treatment expands the therapeutic spectrum and options for reproductive medicine specialists and registering gynaecologists. The availability of conservative treatment in combination with surgical treatment leads to optimalization and greater effectiveness of therapeutic procedures and increased quality of life for women with myomatosis.